Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2016年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled '山东瑞康医药股份有限公司 2016 年半年度报告摘要' which translates to 'Shandong Ruikang Pharmaceutical Co., Ltd. 2016 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period of 2016, including revenue, net profit, cash flow, earnings per share, and asset information. It also includes management discussion and analysis, shareholder information, changes in consolidated scope, and other financial report related matters. The document length is 6467 characters, which is sufficient to contain substantive financial data and analysis. The content matches the characteristics of an Interim / Quarterly Report, as it covers a period shorter than a full fiscal year and includes actual financial statements and management discussion. There is no indication that this is merely an announcement or summary without substantive data, nor is it a full annual report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2016
2016-08-29 Chinese
关于开展应收账款资产证券化的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the initiation of an accounts receivable asset securitization plan. It details the structure, parties involved, and impact of the securitization, including financing scale, asset transfer, and benefits to the company. The text is an official public announcement about a financing activity, specifically asset securitization, which is a form of capital raising. It does not contain financial statements or detailed financial results, nor is it a report or presentation. The document length is short (1899 characters), and it is clearly an announcement of a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-08-29 Chinese
国金证券股份有限公司关于公司使用募集资金置换预先已投入募投项目自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guojin Securities Co., Ltd. regarding Shandong Ruikang Pharmaceutical Co., Ltd.'s use of raised funds to replace self-raised funds previously invested in projects. It references regulatory guidelines on the management and use of raised funds, details about the non-public stock issuance, the amount raised, and the approval process by the board and supervisory committee. The document is a specialized audit or verification report on the use of funds, not a full annual or interim financial report. It does not contain comprehensive financial statements or management discussion but focuses on compliance and verification of fund usage. The document length is about 2130 characters, which is relatively short and focused on a specific audit opinion. Therefore, it fits best under Audit Report / Information (AR) as it is a standalone audit/verification report related to accounting and regulatory compliance of fund usage. FY 2016
2016-08-29 Chinese
第二届董事会第三十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 37th meeting of the second board of directors of Shandong Realcan Pharmaceutical Co., Ltd. It includes nominations for the third board of directors, changes in company name, amendments to the articles of association, approval of business scope changes, use of idle raised funds, asset securitization plans, and other corporate governance matters. It also contains biographies of nominated directors and independent directors. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is not a call transcript or a proxy solicitation. The content focuses on board decisions and management nominations, which fits the category of Board/Management Information (MANG). The document length (8438 characters) and detailed content confirm it is the actual announcement of board resolutions, not a brief report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2016-08-29 Chinese
独立董事候选人声明（于建青）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Shandong Ruikang Pharmaceutical Co., Ltd. It contains detailed statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or report summaries. The content is focused on governance and compliance related to board membership qualifications. This type of document is typically classified under Board/Management Information (MANG) as it pertains to announcements about board members or senior management changes or candidacies.
2016-08-29 Chinese
募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised through multiple stock issuances by 山东瑞康医药股份有限公司 (Shandong Ruikang Pharmaceutical Co., Ltd.). It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and disclosure of raised funds. The document includes extensive financial data on the amounts raised, usage, bank accounts, approvals, and compliance with regulatory requirements. It also contains multiple tables showing the usage of raised funds, investment projects, and approvals by the board and shareholders. The document is not an announcement of a report but the report itself, given its length (over 13,000 characters) and detailed financial and operational data. The content aligns with the definition of a Capital/Financing Update (CAP), as it focuses on fundraising activities, capital raised, and the use of those funds. It is not an Annual Report, Audit Report, or Earnings Release, nor does it fit other categories like Board changes or Legal Proceedings. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.